Inogen Q4 revenue up 5.5% to $80.1M; full-year revenue up 6.4%; operating loss narrows significantly

Inogen Inc

2024-FY EPS reported -$1.52 revenue$335,705,000

Q4 revenue $80.1M (+5.5% YoY); gross margin 45.3% (vs 37.1% YoY) on lower raw material costs and efficiencies.
Q4 GAAP net loss $9.8M improved from $26.6M; adjusted net loss $5.8M; adjusted EBITDA negative $3.6M.
Full-year 2024 revenue $335.7M (+6.4%); operating loss $42.5M (improved from $109.4M); cash $117.4M, no debt.
Company provides 2025 growth outlook; announced strategic collaboration with Yuwell to expand product portfolio and global reach.
Pending U.S. introduction of Simeox airway clearance therapy highlighted as key future growth driver.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.